Document is current
Any future updates will be listed below
-
Authors
Kassim, Sadik H.
Urnov, Fyodor https://orcid.org/0000-0001-7542-4084
Musunuru, Kiran https://orcid.org/0000-0003-3298-0368
Lee, Ann
Barrera, Luis https://orcid.org/0000-0003-0612-6416
Stetkiewicz, Pamela
Bruno, Julianne
Hewitt, Matthew
Lister, Troy
Malech, Harry https://orcid.org/0000-0001-5874-5775
Gasch, Lindsay
Diver, Matt
Gertler, Nicholas
Grignon, Felix
Le, Audrey
Lehmicke, Michael
Horwitz, Edwin M.
Liu, David R.
Lembong, Josephine
Almendro-Navarro, Vanessa
- License Information
-
More Information
Article History
First Online: 15 July 2025
Competing interests
: S.H.K. is an employee and holds equity in Danaher and is an advisor to nChroma Bio. F.U. is an advisor and holds equity in Tune Therapeutics. K.M. is an advisor to and holds equity in Verve Therapeutics and Variant Bio, is an advisor to LEXEO Therapeutics and Capstan Therapeutics, and receives research funding from Nava Therapeutics and Beam Therapeutics. A. Lee is an employee and holds equity in Prime Medicine. L.B. is an employee and holds equity in Beam Therapeutics. P.S. is an employee and holds equity in Arbor Biotechnologies. J.B. is an employee and holds equity in CRISPR Therapeutics. M.H. is an employee and holds equity in Charles River Labs. T.L. is an employee and holds equity in Verve Therapeutics. V.A.-N. is an employee and holds equity in Danaher. H.M. participated as an expert in the field, and opinions expressed by him at the meeting or in this commentary do not represent National Institutes of Health policy or opinion. D.R.L. is a co-founder, consultant, and/or equity holder of Beam Therapeutics, Prime Medicine, Pairwise Plants, nChroma Bio, and Exo Therapeutics.
